ArticleFrontiers in medicine2026
A preclinical investigation into the potential associations of geraniin with ulcerative colitis alleviation through integrated multi-omics and
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the potential molecular mechanisms and alleviating effects of geraniin, a natural polyphenol compound, within a murine model of ulcerative colitis (UC), thereby providing preclinical insights that may inform future translational strategies. Methods: Potential targets of geraniin for UC were identified by screening databases such as the Comparative Toxicogenomics Database and SwissTargetPrediction. UC transcriptomic and single-cell data were sourced from GEO (GSE47908, GSE214695). Differential gene analysis used limma, co-expression modules via WGCNA, enrichment with ClusterProfiler for GO/KEGG, and immune cells via CIBERSORT. Single-cell analysis employed Seurat and AUCell to identify targeted subpopulations. Results: Geraniin targeted 27 genes, which were integrated with 337 UC-related genes to construct a protein-protein interaction network. MCODE analysis identified a key subnetwork comprising 42 genes. GO and KEGG analyses suggested that the potential effects of geraniin may be linked to inflammatory pathways such as IL-17, TNF, and CXCR chemokine signaling. In the single-cell dataset GSE214695, AUCell scores indicated an enrichment of drug targets in macrophage and neutrophil clusters. In this murine model, Conclusion: These findings suggest that geraniin is associated with the alleviation of DSS-induced UC in mice, potentially through the modulation of phenotypic markers related to macrophages and neutrophils.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.